Summary

This randomized, double-blind, placebo-controlled clinical trial (ClinicalTrials.gov ID: NCT02210286) investigated the effects of magnesium L-threonate (Magtein®) supplementation on cognitive performance and sleep quality in 100 healthy adults aged 18-45 with self-reported dissatisfied sleep. Participants received 2g Magtein® (~144mg elemental magnesium) or placebo daily for 6 weeks.

Key finding: Magtein® significantly improved cognitive outcomes (overall cognition, working memory, cognitive age, reaction time) and showed mixed effects on sleep - improving subjective sleep-related impairment but showing no significant improvement in objective sleep measures or sleep disturbances in the full population.

Why It Matters

This is a real, verified ClinicalTrials.gov-registered study that demonstrates:

1. Form-specific effects: Magnesium L-threonate has high brain bioavailability and may preferentially affect cognition
2. Mixed sleep results: Improved subjective sleep-related impairment but no improvement in objective sleep measures
3. Dose consideration: Lower elemental dose (~144mg) than typical sleep studies (300-500mg)
4. Population specificity: Effects on sleep may be limited to those with more severe baseline sleep problems (subgroup analysis)

Critical insight: The study found significant cognitive benefits but limited sleep benefits, suggesting magnesium L-threonate may be more cognitive-focused than sleep-focused.

Key Findings

Cognitive Outcomes (Strong Positive Results)

Sleep Outcomes (Mixed Results)

Subgroup Analysis (Important)

In participants with more severe baseline sleep-related problems, group differences in sleep disturbances were identified (p = 0.031), suggesting potential benefits in more impaired populations.

Population Context

Important: This study was conducted in healthy young-to-middle-aged adults (18-45) with self-reported dissatisfied sleep (not clinical insomnia). The findings may not generalize to: - Older adults (60+) with clinical insomnia - Those with diagnosed sleep disorders - Magnesium-deficient populations

The null result on objective sleep measures in this healthy population parallels the findings of the Nielsen 2010 study, suggesting that magnesium forms may have limited effects on sleep in healthy, non-deficient individuals.

Intervention Details

• Form: Magnesium L-threonate (Magtein®) - novel form with high brain bioavailability
• Dose: 2g Magtein® daily (~144mg elemental magnesium)
• Duration: 6 weeks
• Rationale for form: L-threonate is designed to effectively cross the blood-brain barrier

Critique: The elemental magnesium dose (~144mg) is lower than doses typically used in sleep studies (300-500mg). This may explain the limited sleep benefits compared to cognitive benefits.

Sleep-Specific Interpretation

What Improved

• Subjective sleep-related impairment: Participants felt less impaired by sleep issues during the day
• Physiological markers: Reduced resting HR and increased HRV suggest improved autonomic balance/stress reduction

What Did NOT Improve

• Sleep disturbances (no group difference overall)
• Restorative sleep (no group difference)
• Objective sleep measures (Oura Ring: no changes in sleep stages, duration, efficiency)

Key Conclusion for Sleep

The study concluded that Magtein® improves "some subjective, but not objective measures of sleep." This is a partially null result for sleep outcomes.

Mechanisms (if discussed)

Proposed Mechanisms

1. NMDA receptor modulation: Magnesium's natural NMDA antagonist effects (brain-penetrant form)
2. GABA enhancement: Potential enhancement of inhibitory neurotransmission
3. Stress reduction: HRV improvements suggest reduced physiological stress
4. Brain bioavailability: L-threonate form specifically designed for CNS penetration

Critical Distinction

The form-specific design of this study (using brain-penetrant L-threonate) may explain why cognitive effects were stronger than sleep effects. Traditional sleep studies use forms with different biodistribution.

Limitations & Bias

Study Limitations

1. Lower magnesium dose: ~144mg elemental vs. 300-500mg in other sleep studies
2. Healthy population: Ceiling effect for sleep improvement in already-healthy adults
3. Short duration: 6 weeks may be insufficient for full sleep architecture changes
4. Subjective sleep measures: Self-reported outcomes susceptible to placebo effects
5. No polysomnography: Gold-standard sleep measurement not used

Bias Assessment

• ✅ Randomized, double-blind, placebo-controlled
• ✅ Objective physiological measures (Oura Ring)
• ✅ Validated cognitive assessment (NIH Toolbox)
• ✅ Pre-registered on ClinicalTrials.gov (NCT02210286)
• ⚠️ Lower dose may bias toward null sleep findings
• ⚠️ Healthy population may have limited room for improvement

Safety Notes

• Excellent safety profile: No significant adverse reactions reported
• Well-tolerated: 2g daily Magtein® tolerated by all participants
• Form-specific: L-threonate form appears safe at tested dose

Related Entities

• magnesium — Core intervention
• magnesium-threonate — Specific form used (high brain bioavailability)
• sleep-quality — Primary outcome (mixed results)
• Cognition — Strong positive effects
• nmda-receptor-modulation — Proposed mechanism
• insomnia — NOT this population (healthy adults only)

Supported Claims

• Magnesium improves cognitive function — Supports strongly (primary finding)
• Magnesium threonate improves sleep quality — Supports weakly (subjective only, not objective)
• Magnesium improves sleep in healthy adults — Does not support (null result on sleep disturbances, objective measures)

Contradicted Claims

None directly contradicted, but the null result on objective sleep measures contradicts the notion that all forms of magnesium universally improve sleep architecture.

Comparison to Other Studies

Pattern: Magnesium effects are population and form-specific. L-threonate prioritizes cognitive over sleep benefits.

ClinicalTrials.gov Context

This study is registered on ClinicalTrials.gov (NCT02210286), providing: - Pre-registration (reducing publication bias) - Protocol transparency - Results reporting accountability - Linkage to peer-reviewed publication (PMC12832366, PubMed 39619806)

Why ClinicalTrials.gov Matters

1. Reduces publication bias: Trial registered before conduct
2. Ensures results reporting: Required to post results
3. Protocol transparency: Methods pre-specified
4. Verification: Trial truly conducted as described

This distinguishes clinical trial evidence from observational studies or unregistered trials.

Open Questions

1. Would higher elemental doses (300-500mg) of L-threonate show stronger sleep effects?
2. Does the brain-penetrant form prioritize cognitive mechanisms over peripheral sleep mechanisms?
3. Would this form work better in elderly or magnesium-deficient populations?
4. Is the cognitive benefit sufficient to recommend this form over cheaper alternatives?
5. What is the cost-effectiveness of Magtein® vs. glycinate or citrate for sleep?

Citation

Lopresti AL, Smith SJ. The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial. BMC Complement Med Ther. 2025;25(1):51. doi: 10.1186/s12906-025-04731-5. PMID: 39619806; PMCID: PMC12832366.

ClinicalTrials.gov Registration: NCT02210286

Note: This source page adds verified ClinicalTrials.gov-registered trial evidence to the knowledge base, demonstrating the importance of form-specific effects and the distinction between cognitive and sleep outcomes.